Brief: Harvard Bioscience Q4 revenue USD 28.2 million
07/03/2024 12:04
Mar 7 (Reuters) - Harvard Bioscience Outlook FY gross margin 60%. * Q4 net income USD -1.8 million * Q4 adjusted operating income USD 3.3 million * Q4 adjusted EBITDA USD 3.6 million * Q4 gross margin 58% * Q4 revenue USD 28.2 million * Q4 adjusted EPS USD 0.04
Recent news on Harvard Bioscience
See all newsBrief: Harvard Bioscience Announces Creation Of Scientific Advisory Board
Harvard Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary
Harvard Bioscience Q2 revenue rises on telemetry demand, lifts 2026 outlook
Harvard Bioscience Inc expected to post a loss of 21 cents a share - Earnings Preview
Harvard Bioscience Q1 revenue falls, reaffirms 2026 guidance